ClinicalTrials.gg
CompletedNCT01994837Updated Jun 6, 2018Results posted

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

A Phase 2 interventional study of ABT-199 in Acute Myelogenous Leukemia, AML and Acute Myeloid Leukemia, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
149th of 202
32 · median 57
Started
2013
the only one that year
Phase 2
89 of 202
57 open now
Registered
2nd of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 149th largest by enrollment, is the only one that started in 2013, is one of 89 in phase 2, and was the 2nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This was a Phase 2, open-label, multicenter study evaluating the preliminary efficacy and safety of venetoclax (ABT-199) administered orally in participants with acute myelogenous leukemia (AML).

Read the detailed description

The primary objective was to evaluate the preliminary efficacy of venetoclax administered orally in participants with relapsed and/or refractory (R/R) acute myelogenous leukemia (AML) or frontline therapy in patients with AML who were unfit for intensive therapy. The secondary objective was to evaluate the preliminary safety of venetoclax administered orally in patients with AML. The first portion of the study was to consist of 19 participants with the objective of evaluating anti-tumor effects and confirming the safety of the regimen. The second portion (expansion) was to consist of 35 additional subjects to evaluate anti-tumor effects and safety and was to commence if an adequate efficacy signal (i.e., ≥ 5/19 achieved complete remission [CR], CR with incomplete bone marrow recovery [CRi] or partial remission [PR]) had been observed in the first portion of the study. The criterion for success would have been met if ≥ 16 of 54 participants achieved remission. The efficacy signal from first portion of the study was deemed insufficient for enrollment into the second portion of the study, as 4 of the 19 subjects achieved CR/CRi. During the trial, a number of participants were in screening at the point of the interim analysis. Given the early signs of clinical activity of venetoclax, disease severity, and prognosis of these participants without available options for therapy, they were allowed to initiate treatment ahead of completion of the interim analysis. Therefore, 32 participants were enrolled. No additional participants were screened or treated after the interim analysis was completed.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • AML
  • Acute Myeloid Leukemia

Keywords

  • GDC-0199
  • Acute Myelogenous Leukemia
  • AML
  • ABT-199
  • Acute Myeloid Leukemia
  • Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological confirmation of acute myelogenous leukemia (AML) (by World Health Organization [WHO] classification) or untreated AML in participants who are unfit for intensive therapy.
  2. Participant has an (ECOG) Performance score of 0 to 2.
  3. Participant must have adequate renal function as demonstrated by a calculated ≥ 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula using ideal body mass (IBM) instead of mass.
  4. Participant must have adequate liver function as demonstrated by:

    • (AST) ≤ 3.0 × (ULN)*
    • alanine aminotransferase (ALT) ≤ 3.0 × ULN*
    • ≤ 1.5 × ULN* *unless considered due to leukemic organ involvement. (Participants with Gilbert's Syndrome may have had a bilirubin > 1.5 × ULN per discussion between the investigator and AbbVie medical monitor)

Exclusion criteria

Exclusion Criteria:

  1. Participant has received acute anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any therapy within 14 days or 5 half-lives (whichever is shorter) prior to first dose of ABT-199.
  2. Participant has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
  3. Participant has received potent Cytochrome P450, family 3, subfamily A () inducers (such as rifampin, carbamazepine, phenytoin and St. John's wort) and warfarin or requires the use of warfarin (due to potential drug-drug interactions that may potentially increase the exposure of warfarin and complications of this effect) within 7 days prior to the first dose of study drug.
  4. Participant has received CYP3A inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within 5 days prior to the first dose of study drug.
  5. Participant has a white blood cell count > 25 x 10\^9/L.
  6. Participant has acute promyelocytic leukemia (French-American-British Class M3 AML).
  7. Participants with known active central nervous system (CNS) disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    ABT-199

    Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.

    Drug: ABT-199

Interventions

  • Tablet

    Also known as: ABT-199 also known as venetoclax

06

What researchers measure

Primary outcomes

  1. Objective Remission Rate

    The objective remission rate (ORR) was defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), or partial remission (PR) per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL. Partial remission (PR) was defined as normalization in peripheral blood neutrophil and platelet counts with at least a 50% decrease in blasts persisting in bone marrow versus baseline.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

Secondary outcomes

  1. Complete Remission Rate

    The complete remission (CR) rate was defined as the percentage of participants who achieved CR per the International Working Group criteria for AML. Complete remission was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  2. Duration of Remission

    Duration of remission was defined as the number of days from the date of first remission (CR, CRi, or PR) per the International Working Group criteria for AML to the earliest recurrence or progressive disease (PD). In this study, the duration of remission analysis was not performed because of the low remission rate, per the Statistical Analysis Plan.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  3. Time to Progression

    Time to progression was defined as the number of months from the date of enrollment to the date of earliest disease progression. If a participant did not experience disease progression, then the data for that participant was censored at the date of the last disease assessment.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  4. Progression-free Survival

    Progression-free survival was defined as the number of months from the date of enrollment to the date of earliest progression or death. If a participant did not experience disease progression or death, then the data was censored at the date of the last disease assessment.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  5. Overall Survival

    Overall survival was defined as the number of months from the date of enrollment to the date of death for all dosed participants. For participants who did not die, their data were censored at the date of last study visit or the last known date to be alive, whichever was later.

    Time frame: Measured up to 2 years after the last subject had enrolled in the study.

  6. Percentage of Participants Who Received Subsequent Stem Cell Transplant

    The percentage of participants who received a subsequent allogenic (from a healthy donor) stem cell transplant was summarized.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  7. Rate of Minimal Residual Disease (MRD) Negativity

    The rate of minimal residual disease (MRD) response was defined as the percentage of participants who had MRD negative status. Only participants with a reported MRD assessment (negative or positive) from the local laboratory at the investigator site were used in the calculation of MRD response rate.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  8. Complete Remission With Incomplete Marrow Recovery (CRi) Rate

    The complete remission with incomplete bone marrow recovery (CRi) rate was defined as the percentage of participants who achieved CRi per the International Working Group criteria for AML. Complete remission with incomplete bone marrow recovery was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

  9. Complete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate

    The complete remission rate and the complete remission with incomplete marrow recovery rate (Cri) was defined as the percentage of participants who achieved complete remission (CR) or complete remission with incomplete bone marrow recovery (CRi), per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.

    Time frame: When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

07

Results

Posted Jan 23, 2018

Participant flow

Participant flow — Overall Study
MilestoneABT-199
Started32
Treated32
Completed0
Not completed32
Withdrew: Progressive disease per protocol23
Withdrew: Adv event related to progressive disease3
Withdrew: Fatal progressive disease2
Withdrew: Adverse event not related to progression1
Withdrew: Chose palliative care1
Withdrew: Proceeded to transplant1
Withdrew: Removed from study due to no response1

Outcome measures

PrimaryObjective Remission Rate

The objective remission rate (ORR) was defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), or partial remission (PR) per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL. Partial remission (PR) was defined as normalization in peripheral blood neutrophil and platelet counts with at least a 50% decrease in blasts persisting in bone marrow versus baseline.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Number · percentage of participants
Objective Remission Rate
percentage of participantsABT-199
Objective Remission Rate18.8 (7.2 to 36.4)
SecondaryComplete Remission Rate

The complete remission (CR) rate was defined as the percentage of participants who achieved CR per the International Working Group criteria for AML. Complete remission was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Number · percentage of participants
Complete Remission Rate
percentage of participantsABT-199
Complete Remission Rate6.3
SecondaryDuration of Remission

Duration of remission was defined as the number of days from the date of first remission (CR, CRi, or PR) per the International Working Group criteria for AML to the earliest recurrence or progressive disease (PD). In this study, the duration of remission analysis was not performed because of the low remission rate, per the Statistical Analysis Plan.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier

No measurements were reported for this outcome.

SecondaryTime to Progression

Time to progression was defined as the number of months from the date of enrollment to the date of earliest disease progression. If a participant did not experience disease progression, then the data for that participant was censored at the date of the last disease assessment.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Median · months
Time to Progression
monthsABT-199
Time to Progression2.5 (1.0 to 3.0)
SecondaryProgression-free Survival

Progression-free survival was defined as the number of months from the date of enrollment to the date of earliest progression or death. If a participant did not experience disease progression or death, then the data was censored at the date of the last disease assessment.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Median · months
Progression-free Survival
monthsABT-199
Progression-free Survival2.3 (1.0 to 2.7)
SecondaryOverall Survival

Overall survival was defined as the number of months from the date of enrollment to the date of death for all dosed participants. For participants who did not die, their data were censored at the date of last study visit or the last known date to be alive, whichever was later.

Time frame:
Measured up to 2 years after the last subject had enrolled in the study.
Reported as:
Median · months
Overall Survival
monthsABT-199
Overall Survival4.7 (2.3 to 6.0)
SecondaryPercentage of Participants Who Received Subsequent Stem Cell Transplant

The percentage of participants who received a subsequent allogenic (from a healthy donor) stem cell transplant was summarized.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Number · percentage of participants
Percentage of Participants Who Received Subsequent Stem Cell Transplant
percentage of participantsABT-199
Percentage of Participants Who Received Subsequent Stem Cell Transplant3.1
SecondaryRate of Minimal Residual Disease (MRD) Negativity

The rate of minimal residual disease (MRD) response was defined as the percentage of participants who had MRD negative status. Only participants with a reported MRD assessment (negative or positive) from the local laboratory at the investigator site were used in the calculation of MRD response rate.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Number · percentage of participants
Rate of Minimal Residual Disease (MRD) Negativity
percentage of participantsABT-199
Rate of Minimal Residual Disease (MRD) Negativity43.5 (23.2 to 65.5)
SecondaryComplete Remission With Incomplete Marrow Recovery (CRi) Rate

The complete remission with incomplete bone marrow recovery (CRi) rate was defined as the percentage of participants who achieved CRi per the International Working Group criteria for AML. Complete remission with incomplete bone marrow recovery was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Number · percentage of participants
Complete Remission With Incomplete Marrow Recovery (CRi) Rate
percentage of participantsABT-199
Complete Remission With Incomplete Marrow Recovery (CRi) Rate12.5
SecondaryComplete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate

The complete remission rate and the complete remission with incomplete marrow recovery rate (Cri) was defined as the percentage of participants who achieved complete remission (CR) or complete remission with incomplete bone marrow recovery (CRi), per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.

Time frame:
When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier
Reported as:
Number · percentage of participants
Complete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate
percentage of participantsABT-199
Complete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate18.8 (7.2 to 36.4)

Adverse events

Collected over All adverse events were collected from the time of study drug administration until 30 days after the last dose of study drug, up to 40 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABT-199—27/32 (84.4%)31/32 (96.9%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventABT-199
FEBRILE NEUTROPENIABlood and lymphatic system disorders9/32
MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/32
PNEUMONIAInfections and infestations5/32
ABDOMINAL PAINGastrointestinal disorders2/32
SEPSISInfections and infestations2/32
URINARY TRACT INFECTIONInfections and infestations2/32
FAILURE TO THRIVEMetabolism and nutrition disorders2/32
RENAL FAILURE ACUTERenal and urinary disorders2/32
HYPOTENSIONVascular disorders2/32
ATRIAL FIBRILLATIONCardiac disorders1/32
Most frequent other events
Showing 10 of 78
Most frequent other events
EventABT-199
NAUSEAGastrointestinal disorders19/32
DIARRHOEAGastrointestinal disorders17/32
VOMITINGGastrointestinal disorders13/32
HYPOKALAEMIAMetabolism and nutrition disorders12/32
FATIGUEGeneral disorders11/32
HYPOMAGNESAEMIAMetabolism and nutrition disorders11/32
HEADACHENervous system disorders11/32
HYPOPHOSPHATAEMIAMetabolism and nutrition disorders10/32
COUGHRespiratory, thoracic and mediastinal disorders9/32
OEDEMA PERIPHERALGeneral disorders8/32

Baseline characteristics

All participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)ABT-199
Mean65.9 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)ABT-199
Female16
Male16
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12. PubMed 27520294 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 3 years 1 month after primary completion. A results delay was requested in Dec 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2013
First posted
Nov 26, 2013
Start
Nov 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results delay requested
Dec 18, 2015
Results first posted
Jan 23, 2018
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01994837
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Nov 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jan 23, 2018
Last update
Jun 6, 2018

Study contacts

Jalaja Potluri, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion